ARTICLE

Clinical and epidemiological studies have reported up to 47 % substance-use disorder (SUD) comorbidity in patients with schizophrenia. [1] Addressing SUD comorbidity is clinically relevant since it has a significant impact on the course and prognosis of schizophrenia. For example, it can lead to acute bouts of hospitalisation by reducing patient compliance with antipsychotic treatment.[2] Among psychiatric patients, particularly ones with schizophrenia, comorbidity has been associated with more frequent emergency room visits, criminality, violence, increased fluctuation and severity of psychiatric symptoms, legal problems and family stress.[3-5] Aside from the pharmacological treatments used for reducing symptoms, researchers have started to place greater importance on patient satisfaction, treatment assessment by the patient, and patients’ subjective well-being in the last few years. Thus, researchers ’ emphasi